In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses ...

New data from the single-center, open-label extension EDITA-ON study suggest that early treatment for pulmonary arterial hypertension (PAH) could benefit patients with systemic sclerosis and early ...

Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

Future Cardiol. 2013;9(3):335-349. The pivotal trial that established sildenafil as a treatment for WHO Group 1 PH was the SUPER trial. [102] SUPER enrolled WHO functional class II and III PAH ...

Please provide your email address to receive an email when new articles are posted on . Comparable proportions of patients with vs. without a mental health comorbidity took PAH monotherapy, dual ...

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

A new study has found that asporin, a protein encoded by the ASPN gene, plays a protective role in pulmonary arterial hypertension (PAH). A new study from researchers with UCLA Health and ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

Although more women than men have pulmonary arterial hypertension, several PAH medications are teratogenic, according to a ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human ...

Future Cardiol. 2013;9(3):335-349. Because of the heterogeneity of PH etiology, personalized approaches will likely be needed for successful treatment. Thus, PH is an excellent target for personalized ...